Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma
- 1 January 1995
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (4) , 576-581
- https://doi.org/10.1016/0959-8049(95)00052-k
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reactionBritish Journal of Cancer, 1994
- Carrier-free 131I-meta-iodobenzylguanidineNuclear Medicine Communications, 1994
- 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizesBritish Journal of Cancer, 1992
- The uptake and retention of metaiodobenzyl guanidine by the neuroblastoma cell line NB1-GBritish Journal of Cancer, 1991
- Implications of the uptake of 131I-radiolabelled metaiodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastomaThe British Journal of Radiology, 1991
- Meta‐Iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK‐N‐BE(2C)International Journal of Cancer, 1991
- Diagnosis and treatment of malignant pheochromocytoma with 131I-meta-iodobenzylguanidine: a case reportRadiotherapy and Oncology, 1990
- Influence of specific activity on myocardial uptake of 123I-mIBG in ratsNuclear Medicine Communications, 1988
- Growth delay in small EMT6 spheroids induced by cytotoxic drugs and its modification by misonidazole pretreatment under hypoxic conditionsBritish Journal of Cancer, 1982
- Solid-phase exchange radioiodination of aryl iodides. Facilitation by ammonium sulfateThe Journal of Organic Chemistry, 1982